Intermittent 2-Hour-Infusion of Cladribine as First-Line Therapy or in First Relapse of Progressive Advanced Low-Grade and Mantle Cell Lymphomas

References

• The Non-Hodgkin's Lymphoma pathologic classification project National Cancer Institute sponsored study of classifications of non-Hodghn's lymphomas. Summary and description of a Working Formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Histopathologie der Non-Hodgkin Lymphome (nach der aktualisierten Eel-Klassifikation), K. Lennert, A. C. Feller. Springer, Berlin-Heidelberg-New York 1990
   Google Scholar
• Homing S. J., Rosenberg S. A. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Beutler E. Cladribine (2-Chlorodeoxyadenosine). Lancer 1992; 340: 952–956
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Taetle R., et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–743
   PubMed Web of Science ®Google Scholar
• Seto S., Camera C. J., Kubota M., et al. Mechanism of deoxyadenosine and 2-chlorode-oxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75: 377–383
   PubMed Web of Science ®Google Scholar
• Kay A. C., Saven A., Camera C. J., et al. 2-Chloro-deoxyadenosine in low grade lymphoma. J Clin Oncol 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Hickish T., Serafinowski P., Cunningham D., et al. 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer. 1993; 67: 139–143
   PubMed Web of Science ®Google Scholar
• Hoffman M., Tallman M. S., Hakimian D., et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodkin's lymphoma. J Clin Oncol. 1994; 12: 788–792
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Weber D., Delasalle K. B., et al. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors. Ann Oncol 1995; 6: 49–52
   PubMed Web of Science ®Google Scholar
• Liliemark J., Ponvit A., Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkh's lymphoma. Leuk Lymph 1997; 25: 313–318
   PubMed Web of Science ®Google Scholar
• Robak T., Géra-Tybor J., Krykowski E., et al. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma. Leuk Lymph 1997; 26: 99–105
   PubMed Web of Science ®Google Scholar
• Rondelli D., Lauria E, Zinzani P. L., et al. 2-Chlorodeoxyadenosine in the treatment of relapsedlrefractory chronic lymphoproliferative disorders. Eur J Haematol 1997; 58: 46–50
   PubMed Web of Science ®Google Scholar
• Harris N. J., Jaffe E. S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Hanington D. P. A., jr, Armitage J. O., et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Kantarjian H., Weber D., et al. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12: 2694–2698
   PubMed Web of Science ®Google Scholar
• Saven A., Emanuele S., Kosty M., et al. 2-chlorcdeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995; 86: 1710–1716
   PubMed Web of Science ®Google Scholar
• Betticher D. C., Zucca E., von Rohr A., et al. 2-chlorodeoxyadenosine (2-CdA) therapy in previously untreated patients with follicular stage 111-IV non-Hodgkin's lymphoma. Ann Oncol 1996; 7: 793–799
   PubMed Web of Science ®Google Scholar
• Canfield V. A., Vose J., Guiney P., et al. 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas. Leuk Lymph 1997; 24: 335–339
   PubMed Web of Science ®Google Scholar
• Liliemark J., Juliusson G. Cellular pharmacoki-netics of 2-chloro-2-deoxyadenosine nucleotides: comparison of intermittent and continous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cam Rex 1995; 1: 385–390
   PubMed Web of Science ®Google Scholar
• Liliemark J., Martinsson U., Cavallin-Stahl E., et al. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma. Leuk Lymph 1998; 30: 573–581
   PubMed Web of Science ®Google Scholar
• Annitage J. O., et al. The non-Hodgkin's lymphoma classification project: A clinical evaluation of the intemational lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Brittinger G., Bartels H., Common H., et al. Kli-nische und prognostische Relevanz der Kiel-Klassifikation der non-Hodgkin Lymphome. Onkologie 1986; 9: 118–125
   PubMedGoogle Scholar
• Zucca E., Fontana S., Roggero E., et al. Treatment and prognosis of centrocytic (mantle cell) lymphoma: A retrospective analysis of twenty-six patients treated in one institution. Leuk Lymph 1994; 13: 105–110
   PubMed Web of Science ®Google Scholar
• Zucca E., Roggero E., Pinotti G., et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257–262
   PubMed Web of Science ®Google Scholar
• Estey E. H., Kurzrock R., Kantarjian H. M., et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882487
   Web of Science ®Google Scholar
• Unterhalt M., Hemnann R., Tiemann M., et al. Pred-nimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodglun's lymphoma. Leukemia 1996; 10: 836–843
   PubMed Web of Science ®Google Scholar
• Betticher D. C., Fey M. F., von Rohr A., et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute Ieukaemias. Ann Oncol 1994; 5: 5764
   Web of Science ®Google Scholar
• Saven A., Burian C., Koziol J., et al. Lomg-term follow up of patients with hairy cell leukemia (HCL) following cladribine treatment. Blood 1997; 90%(Suppl 1)578a, (Abstr 2573).
   PubMed Web of Science ®Google Scholar
• Kumock R., Strom S. S., Estey E., et al. Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 1997; 15: 1803–1810
   PubMed Web of Science ®Google Scholar
• Karlsson K., Stramberg M., Johnson S., et al. Three-day three-weekly oral cladribine (2-CdA) for chronic lymphocytic leukemia. A preliminary report from a European phase I1 multicenter study. Ann Oncol 1996; 7%(Suppl 3)68, (Abstr 239).
   Google Scholar
• Betticher D. C., von Rohr A., Ratschiller D., et al. Fewer infections, but maintained antitumor activity with lowerdose versus standarddose cladribine in prcmatcd low-grade non-Hodglan's lymphoma. J Clin Oncol 1998; 16: 850–858
   PubMed Web of Science ®Google Scholar
• Betticher D. C., Ratschiller D., Hsu Schmitz S. F., et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia. Ann. Oncol 1998; 9: 721–726
   Google Scholar
• Saven A., Lee T., Kosty M., Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 2139–2144
   PubMed Web of Science ®Google Scholar
• Mitrou P. S., Chow K. U., Rummel M., et al. Syner-gistic effects of 2-CdA and other cytotoxic drugs on apopto-sis of nonnal and malignant lymphocytes. J Concer Res Clin Oncol. 1998; 124%(Suppl), R59 (Abstr 14.28.02).
   Google Scholar